Joseph B Babigumira1,2, Solomon J Lubinga1,2, Emma Castro3, Brian Custer4,5. 1. Global Medicines Program, Department of Global Health, University of Washington, Seattle, United States of America. 2. Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, United States of America. 3. Community Blood Transfusion Centre, Valencia, Spain. 4. Blood Systems Research Institute, San Francisco, United States of America. 5. Department of Laboratory Medicine, UCSF, San Francisco, United States of America.
Abstract
BACKGROUND: Methylene blue and visible light treatment and quarantine are two methods used to reduce adverse events, mostly infections, associated with the transfusion of fresh-frozen plasma. The objective of this study was to estimate and compare the budget impact and cost-utility of these two methods from a payer's perspective. MATERIALS AND METHODS: A budget impact and cost-utility model simulating the risks of hepatitis B virus, hepatitis C virus, cytomegalovirus, a West Nile virus-like infection, allergic reactions and febrile non-haemolytic transfusion reactions achieved using plasma treated with methylene blue and visible light (MBP) and quarantine plasma (QP) was constructed for Spain. QP costs were estimated using data from one blood centre in Spain and published literature. The costs of producing fresh-frozen plasma from whole blood, apheresis plasma, and multicomponent apheresis, and separately for passive and active methods of donor recall for QP were included. Costs and outcomes over a 5-year and lifetime time horizon were estimated. RESULTS: Compared to passive QP, MBP led to a net increase of € 850,352, and compared to active QP, MBP led to a net saving of € 5,890,425 over a 5-year period. Compared to passive QP, MBP increased the cost of fresh-frozen plasma per patient by € 7.21 and had an incremental cost-utility ratio of € 705,126 per quality-adjusted life-year. Compared to active QP, MBP reduced cost by € 50.46 per patient and was more effective. DISCUSSION: Plasma collection method and quarantine approach had the strongest influence on the budget impact and cost-utility of MBP. If QP relies on plasma from whole blood collection and passive quarantine, it is less costly than MBP. However, MPB was estimated to be more effective than QP in all analyses.
BACKGROUND:Methylene blue and visible light treatment and quarantine are two methods used to reduce adverse events, mostly infections, associated with the transfusion of fresh-frozen plasma. The objective of this study was to estimate and compare the budget impact and cost-utility of these two methods from a payer's perspective. MATERIALS AND METHODS: A budget impact and cost-utility model simulating the risks of hepatitis B virus, hepatitis C virus, cytomegalovirus, a West Nile virus-like infection, allergic reactions and febrile non-haemolytic transfusion reactions achieved using plasma treated with methylene blue and visible light (MBP) and quarantine plasma (QP) was constructed for Spain. QP costs were estimated using data from one blood centre in Spain and published literature. The costs of producing fresh-frozen plasma from whole blood, apheresis plasma, and multicomponent apheresis, and separately for passive and active methods of donor recall for QP were included. Costs and outcomes over a 5-year and lifetime time horizon were estimated. RESULTS: Compared to passive QP, MBP led to a net increase of € 850,352, and compared to active QP, MBP led to a net saving of € 5,890,425 over a 5-year period. Compared to passive QP, MBP increased the cost of fresh-frozen plasma per patient by € 7.21 and had an incremental cost-utility ratio of € 705,126 per quality-adjusted life-year. Compared to active QP, MBP reduced cost by € 50.46 per patient and was more effective. DISCUSSION: Plasma collection method and quarantine approach had the strongest influence on the budget impact and cost-utility of MBP. If QP relies on plasma from whole blood collection and passive quarantine, it is less costly than MBP. However, MPB was estimated to be more effective than QP in all analyses.
Authors: Mario Eandi; Giorgio Gandini; Massimiliano Povero; Orietta Zaniolo; Lorenzo Pradelli; Giuseppe Aprili Journal: Blood Transfus Date: 2015-01 Impact factor: 3.443
Authors: C Politis; L Kavallierou; S Hantziara; M Parara; E Zervou; O Katsarou; M Hatzitaki; P Fountouli; A Gioka; K Tzioura; S Koumarianos; M Asariotou; C Richardson Journal: Transfus Med Date: 2014-09-29 Impact factor: 2.019
Authors: Nancy M Heddle; Michael Boeckh; Brenda Grossman; Jessica Jacobson; Steven Kleinman; Aaron A R Tobian; Kathryn Webert; Edward C C Wong; John D Roback Journal: Transfusion Date: 2016-03-10 Impact factor: 3.157
Authors: Berlian I Idris; Max Brosa; Jan H Richardus; Rafael Esteban; Solko W Schalm; Maria Buti Journal: Eur J Gastroenterol Hepatol Date: 2008-04 Impact factor: 2.566
Authors: Julio Lopez-Bastida; Juan Oliva-Moreno; Lilisbeth Perestelo-Perez; Pedro Serrano-Aguilar Journal: BMC Health Serv Res Date: 2009-03-30 Impact factor: 2.655